Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351533 | 0.95 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7108497 | 0.90 | GRIN1 (0.43) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2A | |
| SCHEMBL2220242 | 0.90 | GRIN1 (0.43) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2A | |
| SCHEMBL11369540 | 0.84 | MAPK1 (0.39) | GRIN1GRIN2A | |
| SCHEMBL13221438 | 0.79 | SLC6A3 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL38663972 | 0.78 | SLC6A3 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22261434 | 0.77 | NPC1 (0.34) | SLC6A4SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL27479696 | 0.75 | GRIN1 (0.33) | SLC6A2SLC6A4GRIN1GRIN2ACHRM2 | |
| SCHEMBL13221433 | 0.74 | MAOB (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29137636 | 0.72 | KMT2A (0.31) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | SLC6A2 136/4885SLC6A4 74/4885SLC6A3 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.